Compare RCAT & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | SLDB |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2017 | 2017 |
| Metric | RCAT | SLDB |
|---|---|---|
| Price | $7.96 | $8.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $20.00 | $16.36 |
| AVG Volume (30 Days) | ★ 6.7M | 751.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,836,382.00 | $8,094,000.00 |
| Revenue This Year | $271.60 | N/A |
| Revenue Next Year | $41.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.95 | N/A |
| 52 Week Low | $5.77 | $3.79 |
| 52 Week High | $18.78 | $11.45 |
| Indicator | RCAT | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | 45.19 |
| Support Level | $7.53 | $6.25 |
| Resistance Level | $8.85 | $11.45 |
| Average True Range (ATR) | 0.46 | 0.42 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 4.83 | 14.18 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.